Brindoxime is an organic compound with antimalarial and anti-RNA-virus activity

Brofezil (ICI 54594) is an ibuprofen derivative with anti-inflammatory and analgesic activity.

Dapabutan an antiseptic bacteriostatic drug, active against Gram-positive bacteria. Dapabutan is a component of a local antiseptic drug Sterlane.

Brinazarone (SR33557) is a calcium channel blocker, that inhibits acid sphingomyelinase activity and enhances ricin-A chain immunotoxin activity. Brinazarone may act, much like perhexiline, by disturbing membrane lipid composition through their inhibitory action on lysosomal phospholipid hydrolases, such as acid sphingomyelinase, leading to modifications in intracellular routing and to subsequent degradation of ricin-A chain immunotoxins.

Danosteine is an alkylthioacetic acid, developed by the French company Joullie International. The compound is claimed to have mucolytic action, demonstrated by inhibition of endobronchial retention of mucus induced by inhalation of SO2 in rats.

Diclometide is the antipsychotic agent.

FENPRINAST is a cromotyn-like bronchodilator used for the treatment of allergy and exercise-induced asthma.

Iolixanic Acid is triiodophenoxyalkoxyalkanoic acid derivative patented by Bracco Industria Chimica S.p.A. as diagnostic agent for cholecystography.

Perfluoro tert-butylcyclohexane (PTBCH) is a perfluorocarbon emulsion that acts as a highly effective oxygen carrier compared to blood. Administration of PTBCH significantly increased parenchymal tissue oxygen levels during the usual post-injury hypoxic phase, and PTBCH has been shown to be effective in stroke and head injury. Administration of PTBCH during cardiopulmonary bypass was associated with an excessive release of cytokines. This enhanced inflammatory response with subsequent hypotension may have contributed to mortality in rats receiving PTBCH. The observed patterns of myocardial injury indicate global hypoperfusion and catecholamine excess.

Levosemotiadil is an S-enantiomer of semotiadil. It is an antiarrhythmic drug with sodium and calcium channel blocking action, as well as potassium blocking activity. Levosemotiadil is bound strongly and enantioselectively to human serum albumin and human alpha1-acid glycoprotein. Since levosemotiadil is hydrophobic basic drug, it is likely that this drug is also bound to lipoprotein in human plasma. Levosemotiadil might be effective in prevention of lethal arrhythmias. It was shown, that levosemotiadil prevented ventricular fibrillation in 64% of the high-risk animals. Heart rate responses to myocardial ischemia and to graded doses of isoproterenol were blunted by the high dose of levosemotiadil. Levosemotiadil had been in phase II clinical trials by Santen Pharmaceutical for the treatment of arrhythmias. However, this study was discontinued.